William Blair Has Optimistic Outlook of LENZ FY2024 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Investment analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a report released on Wednesday, November 6th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($2.28) per share for the year, up from their prior forecast of ($2.44). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.09) per share. William Blair also issued estimates for LENZ Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.97) EPS and FY2025 earnings at ($2.87) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the previous year, the business earned ($1.33) earnings per share.

A number of other equities analysts also recently commented on LENZ. Piper Sandler reissued an “overweight” rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Finally, Raymond James assumed coverage on LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $35.40.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ opened at $35.75 on Monday. The firm has a 50-day simple moving average of $25.18 and a 200-day simple moving average of $21.42. LENZ Therapeutics has a one year low of $14.07 and a one year high of $37.13.

Institutional Investors Weigh In On LENZ Therapeutics

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new position in LENZ Therapeutics in the 1st quarter worth $362,000. Vanguard Group Inc. acquired a new stake in shares of LENZ Therapeutics during the first quarter worth about $4,621,000. American International Group Inc. purchased a new stake in LENZ Therapeutics in the first quarter valued at approximately $44,000. Jacobs Levy Equity Management Inc. purchased a new stake in LENZ Therapeutics in the first quarter valued at approximately $830,000. Finally, Ikarian Capital LLC acquired a new position in LENZ Therapeutics in the 1st quarter worth approximately $1,898,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.